InflaRx's INF904 Will Initially Target Chronic Spontaneous Urticaria And Hidradenitis Suppurativa, With Initiation Of A Phase 2a PK Dose-ranging Study Expected By The End Of 2024, With Data Availability Anticipated In 2025
InflarX 的 INF904 最初将针对慢性自发性荨麻疹和化脓性汗腺炎,预计将于 2024 年底启动 2a 期 PK 剂量范围研究,预计将于 2025 年提供数据